FRANKLIN LAKES, N.J., March 1, 2016 – BD (Becton, Dickinson and Company), a leading global medical technology company, announced today that it obtained the CE mark in Europe for a next-generation blood separation technology that is designed to enhance sample quality, improve laboratory efficiency and reduce laboratory turnaround time.
BD Vacutainer® Barricor™ tube is a single-use, plastic evacuated tube used to collect, separate, transport and process venous blood specimens to obtain high-quality plasma for in vitro diagnostic use.
The design complements BD Vacutainer® evacuated blood collection tubes, and continues the BD heritage of ensuring best practice in the collection, transportation and processing of blood samples. BD Barricor™ tubes are optimized to deliver a high quality plasma sample by reducing cellular content (vs. plasma gel tubes), as a result of the mechanical separator remaining open throughout the centrifugation cycle. It eliminates gel artifacts which can lead to instrument downtime. These factors together with longer sample stability can significantly improve the sample and laboratory workflow.
According to the American Journal of Clinical Pathology, with 60 to 70 percent of the required information on a patient’s chart coming from laboratory test results, there is a high demand for rapid test turnaround time among clinicians.1 BD Barricor tubes deliver a faster time-to-result for patients – with no clotting time required and a reduction in centrifugation time of up to 7 minutes, an overall saving in turnaround time of 37 minutes is possible.
“Laboratory technicians are forced to choose between a clean sample with serum and a fast sample with plasma,” said Lisa Nibauer, vice president and general manager of Global Marketing for BD Life Sciences. “BD Barricor tubes eliminate this tradeoff, providing a cleaner and faster plasma sample than current methods.”
The new BD Vacutainer Barricor Plasma Blood Collection tube has a revolutionary separator technology, providing a cleaner plasma sample with less cellular contamination, meaning the sample is more stable and allows a longer window to conduct testing when compared to existing blood separation tubes.
For more information, please visit: www.bd.com.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.
1Holland, L.L., Smith, L.L., & Blick, K.E. (2005). Reducing laboratory turnaround time outliers can reduce emergency patient length of stay. American Journal of Clinical Pathology, 124, 672-674.